Globus Medical, Inc. (GMED)
NYSE: GMED · Real-Time Price · USD
87.81
+0.71 (0.82%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Globus Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,939 | 2,519 | 1,568 | 1,023 | 958.1 | Upgrade
|
| Revenue Growth (YoY) | 16.65% | 60.62% | 53.34% | 6.76% | 21.43% | Upgrade
|
| Cost of Revenue | 938.35 | 819.88 | 476.52 | 262.83 | 239.22 | Upgrade
|
| Gross Profit | 2,001 | 1,699 | 1,092 | 760.01 | 718.88 | Upgrade
|
| Selling, General & Admin | 1,135 | 977.48 | 643.41 | 432.12 | 408.15 | Upgrade
|
| Research & Development | 146.94 | 161.6 | 124.01 | 73.02 | 97.35 | Upgrade
|
| Amortization of Goodwill & Intangibles | 118.19 | 119.37 | 51.03 | 17.74 | 18.53 | Upgrade
|
| Operating Expenses | 1,400 | 1,258 | 818.45 | 522.87 | 524.02 | Upgrade
|
| Operating Income | 600.27 | 441.03 | 273.51 | 237.15 | 194.86 | Upgrade
|
| Interest Expense | - | -4.19 | - | - | - | Upgrade
|
| Interest & Investment Income | 7.14 | - | 20.13 | 14.23 | 9.3 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.01 | -43.29 | 14.26 | -1.02 | -1.42 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.41 | 2.21 | -2.14 | 7.24 | 3.36 | Upgrade
|
| EBT Excluding Unusual Items | 607.82 | 395.76 | 305.76 | 257.6 | 206.09 | Upgrade
|
| Merger & Restructuring Charges | -77.35 | -274.72 | -139.93 | -6.85 | -16.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -5.39 | -2.78 | Upgrade
|
| Legal Settlements | -43.1 | -0.31 | -0.43 | -2.34 | -5.92 | Upgrade
|
| Other Unusual Items | 117.7 | - | - | - | - | Upgrade
|
| Pretax Income | 605.07 | 120.72 | 165.39 | 243.02 | 180.41 | Upgrade
|
| Income Tax Expense | 67.2 | 17.74 | 42.52 | 52.85 | 31.22 | Upgrade
|
| Net Income | 537.87 | 102.98 | 122.87 | 190.17 | 149.19 | Upgrade
|
| Net Income to Common | 537.87 | 102.98 | 122.87 | 190.17 | 149.19 | Upgrade
|
| Net Income Growth | 422.28% | -16.19% | -35.39% | 27.47% | 45.86% | Upgrade
|
| Shares Outstanding (Basic) | 135 | 136 | 113 | 100 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 137 | 138 | 115 | 103 | 104 | Upgrade
|
| Shares Change (YoY) | -0.58% | 20.27% | 11.68% | -0.95% | 2.63% | Upgrade
|
| EPS (Basic) | 3.98 | 0.76 | 1.09 | 1.89 | 1.48 | Upgrade
|
| EPS (Diluted) | 3.92 | 0.75 | 1.07 | 1.85 | 1.44 | Upgrade
|
| EPS Growth | 422.67% | -29.91% | -42.16% | 28.47% | 42.57% | Upgrade
|
| Free Cash Flow | 588.77 | 405.21 | 165.23 | 104.42 | 219.38 | Upgrade
|
| Free Cash Flow Per Share | 4.30 | 2.94 | 1.44 | 1.02 | 2.12 | Upgrade
|
| Gross Margin | 68.07% | 67.46% | 69.62% | 74.30% | 75.03% | Upgrade
|
| Operating Margin | 20.42% | 17.51% | 17.44% | 23.18% | 20.34% | Upgrade
|
| Profit Margin | 18.30% | 4.09% | 7.83% | 18.59% | 15.57% | Upgrade
|
| Free Cash Flow Margin | 20.03% | 16.08% | 10.53% | 10.21% | 22.90% | Upgrade
|
| EBITDA | 877.11 | 694.42 | 419.03 | 305.4 | 264.73 | Upgrade
|
| EBITDA Margin | 29.84% | 27.56% | 26.72% | 29.86% | 27.63% | Upgrade
|
| D&A For EBITDA | 276.84 | 253.39 | 145.53 | 68.25 | 69.87 | Upgrade
|
| EBIT | 600.27 | 441.03 | 273.51 | 237.15 | 194.86 | Upgrade
|
| EBIT Margin | 20.42% | 17.51% | 17.44% | 23.18% | 20.34% | Upgrade
|
| Effective Tax Rate | 11.11% | 14.69% | 25.71% | 21.75% | 17.30% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.